Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to ...

Maze Therapeutics (MAZE) announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in ...

Kidney disease affects millions of Americans, with Black communities facing disproportionately higher risks due to genetic factors, socioeconomic challenges, ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

The most advanced Maze program is MZE829, a small molecule designed to inhibit apolipoprotein L1, or APOL1. This protein is associated with a higher risk of kidney disease. People of African ...

Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.

Today's news roundup covers Graphnet's new AF screening tool and Maidstone Hospital's 100th robotic surgery patient.

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

MZE829 is in a phase 2 trial in APOL1 kidney disease (AKD), with results expected in 2026, while MZE782 is currently in a phase 1 healthy volunteer study and is a potential therapy for chronic ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...